You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClevidipine
Accession NumberDB04920
TypeSmall Molecule
GroupsApproved
DescriptionClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Structure
Thumb
Synonyms
Clevidipine butyrate
External Identifiers
  • H-324/38
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cleviprexemulsion.5 mg/mLintravenousThe Medicines Company2008-09-15Not applicableUs
Cleviprexemulsion0.5 mgintravenousThe Medicines CompanyNot applicableNot applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII19O2GP3B7Q
CAS number167221-71-8
WeightAverage: 456.316
Monoisotopic: 455.090242887
Chemical FormulaC21H23Cl2NO6
InChI KeyInChIKey=KPBZROQVTHLCDU-UHFFFAOYSA-N
InChI
InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
IUPAC Name
methyl 5-{[(butanoyloxy)methoxy]carbonyl}-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate
SMILES
CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Tricarboxylic acid or derivatives
  • Dihydropyridinecarboxylic acid derivative
  • 1,2-dichlorobenzene
  • Acylal
  • Halobenzene
  • Fatty acid ester
  • Chlorobenzene
  • Fatty acyl
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Carboxylic acid ester
  • Azacycle
  • Enamine
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension.
PharmacodynamicsClevidipine belongs to a well-known class of drugs called dihydropyridine calcium channel antagonists. Clevidpine is the first third generation intravenous dihydropyridine calcium channel blocker. In vitro studies demonstrated that clevidipine acts by selectively relaxing the smooth muscle cells that line small arteries, resulting in arterial dilation, widening of the artery opening, and without reducing central venous pressure or reducing cardiac output.
Mechanism of actionPossibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding>99.5%
Metabolism

Clevidipine is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood.

Route of eliminationurine 63-74%, feces 7-22%
Half life1 minute
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9887
Blood Brain Barrier-0.5892
Caco-2 permeable+0.6566
P-glycoprotein substrateSubstrate0.5787
P-glycoprotein inhibitor IInhibitor0.8948
P-glycoprotein inhibitor IINon-inhibitor0.6827
Renal organic cation transporterNon-inhibitor0.8312
CYP450 2C9 substrateNon-substrate0.8879
CYP450 2D6 substrateNon-substrate0.8693
CYP450 3A4 substrateSubstrate0.693
CYP450 1A2 substrateInhibitor0.6871
CYP450 2C9 inhibitorInhibitor0.6818
CYP450 2D6 inhibitorNon-inhibitor0.8455
CYP450 2C19 inhibitorInhibitor0.7456
CYP450 3A4 inhibitorInhibitor0.9187
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9098
Ames testNon AMES toxic0.7527
CarcinogenicityNon-carcinogens0.8407
BiodegradationNot ready biodegradable0.9403
Rat acute toxicity2.6248 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7841
hERG inhibition (predictor II)Non-inhibitor0.8148
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Emulsionintravenous.5 mg/mL
Emulsionintravenous0.5 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5739152 No1995-04-142015-04-14Us
US5856346 No2001-01-052021-01-05Us
US8658676 No2011-10-102031-10-10Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00267 mg/mLALOGPS
logP4.98ALOGPS
logP4.09ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)5.31ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area90.93 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity113.93 m3·mol-1ChemAxon
Polarizability45.12 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
  2. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]
  3. Wang QD, Segawa D, Ericsson H, Sjoquist PO, Johansson L, Ryden L: Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. J Cardiovasc Pharmacol. 2002 Aug;40(2):228-34. [PubMed:12131552 ]
  4. Stephens CT, Jandhyala BS: Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002 May;24(4):301-13. [PubMed:12069360 ]
External Links
ATC CodesC08CA16
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (381 KB)
MSDSDownload (568 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Clevidipine can be increased when it is combined with Abiraterone.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clevidipine.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Clevidipine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Clevidipine.
AliskirenThe risk or severity of adverse effects can be increased when Clevidipine is combined with Aliskiren.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Clevidipine.
AmiodaroneThe metabolism of Clevidipine can be decreased when combined with Amiodarone.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clevidipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Clevidipine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Clevidipine.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Clevidipine.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Clevidipine.
AripiprazoleAripiprazole may increase the hypotensive activities of Clevidipine.
ArtemetherThe metabolism of Clevidipine can be decreased when combined with Artemether.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Clevidipine.
AtomoxetineThe metabolism of Clevidipine can be decreased when combined with Atomoxetine.
AtosibanThe risk or severity of adverse effects can be increased when Clevidipine is combined with Atosiban.
Atracurium besylateClevidipine may increase the neuromuscular blocking activities of Atracurium besylate.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Clevidipine is combined with Azilsartan medoxomil.
AzithromycinThe metabolism of Clevidipine can be decreased when combined with Azithromycin.
BarbitalBarbital may increase the hypotensive activities of Clevidipine.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Clevidipine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Clevidipine.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Clevidipine.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Clevidipine.
BortezomibThe metabolism of Clevidipine can be decreased when combined with Bortezomib.
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Clevidipine.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clevidipine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clevidipine.
BupropionThe metabolism of Clevidipine can be decreased when combined with Bupropion.
CaffeineThe metabolism of Clevidipine can be decreased when combined with Caffeine.
CanagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Clevidipine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Clevidipine.
CarbamazepineThe metabolism of Clevidipine can be increased when combined with Carbamazepine.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Clevidipine.
CarvedilolCarvedilol may increase the hypotensive activities of Clevidipine.
CarvedilolThe risk or severity of adverse effects can be increased when Clevidipine is combined with Carvedilol.
CelecoxibThe metabolism of Clevidipine can be decreased when combined with Celecoxib.
ChloroquineThe metabolism of Clevidipine can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clevidipine.
ChlorpromazineThe metabolism of Clevidipine can be decreased when combined with Chlorpromazine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clevidipine.
CholecalciferolThe metabolism of Clevidipine can be decreased when combined with Cholecalciferol.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Clevidipine.
CimetidineThe metabolism of Clevidipine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Clevidipine can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Clevidipine can be decreased when combined with Citalopram.
ClemastineThe metabolism of Clevidipine can be decreased when combined with Clemastine.
ClobazamThe metabolism of Clevidipine can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Clevidipine can be decreased when combined with Clomipramine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clevidipine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine.
ClotrimazoleThe metabolism of Clevidipine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clevidipine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Clevidipine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Clevidipine can be decreased when combined with Cocaine.
Cyproterone acetateThe serum concentration of Clevidipine can be decreased when it is combined with Cyproterone acetate.
DapagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Clevidipine.
DarifenacinThe metabolism of Clevidipine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Clevidipine can be increased when it is combined with Darunavir.
DeferasiroxThe serum concentration of Clevidipine can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Clevidipine can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Clevidipine can be decreased when combined with Desipramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clevidipine.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Clevidipine.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Clevidipine.
DinutuximabThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dinutuximab.
DiphenhydramineThe metabolism of Clevidipine can be decreased when combined with Diphenhydramine.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Clevidipine.
DisulfiramThe metabolism of Clevidipine can be decreased when combined with Disulfiram.
DoxazosinDoxazosin may increase the hypotensive activities of Clevidipine.
DoxazosinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Doxazosin.
DronedaroneThe metabolism of Clevidipine can be decreased when combined with Dronedarone.
DuloxetineClevidipine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Clevidipine can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.
EliglustatThe metabolism of Clevidipine can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Clevidipine.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Clevidipine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clevidipine.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Clevidipine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clevidipine.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.
FluconazoleThe serum concentration of Clevidipine can be increased when it is combined with Fluconazole.
FluoxetineThe metabolism of Clevidipine can be decreased when combined with Fluoxetine.
FluvoxamineThe metabolism of Clevidipine can be decreased when combined with Fluvoxamine.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Clevidipine.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Clevidipine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.
HaloperidolThe metabolism of Clevidipine can be decreased when combined with Haloperidol.
HexobarbitalHexobarbital may increase the hypotensive activities of Clevidipine.
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Clevidipine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clevidipine.
ImipramineThe metabolism of Clevidipine can be decreased when combined with Imipramine.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Clevidipine.
IndinavirThe metabolism of Clevidipine can be decreased when combined with Indinavir.
IndoraminIndoramin may increase the hypotensive activities of Clevidipine.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clevidipine.
IsoniazidThe metabolism of Clevidipine can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clevidipine.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Clevidipine.
IsoxsuprineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clevidipine.
KetoconazoleThe metabolism of Clevidipine can be decreased when combined with Ketoconazole.
LabetalolLabetalol may increase the hypotensive activities of Clevidipine.
LabetalolThe risk or severity of adverse effects can be increased when Clevidipine is combined with Labetalol.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Clevidipine.
LevodopaClevidipine may increase the orthostatic hypotensive activities of Levodopa.
LidocaineThe metabolism of Clevidipine can be decreased when combined with Lidocaine.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.
LopinavirThe metabolism of Clevidipine can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Clevidipine can be decreased when combined with Lorcaserin.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Clevidipine.
LumefantrineThe metabolism of Clevidipine can be decreased when combined with Lumefantrine.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Clevidipine.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.
MethadoneThe metabolism of Clevidipine can be decreased when combined with Methadone.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Clevidipine.
MethohexitalMethohexital may increase the hypotensive activities of Clevidipine.
MethotrimeprazineThe metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clevidipine.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Clevidipine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Clevidipine.
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clevidipine.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Clevidipine.
MexiletineThe metabolism of Clevidipine can be decreased when combined with Mexiletine.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clevidipine.
MirabegronThe metabolism of Clevidipine can be decreased when combined with Mirabegron.
MivacuriumClevidipine may increase the neuromuscular blocking activities of Mivacurium.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Clevidipine.
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Clevidipine.
NafcillinThe metabolism of Clevidipine can be increased when combined with Nafcillin.
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Clevidipine.
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Clevidipine.
NevirapineThe metabolism of Clevidipine can be decreased when combined with Nevirapine.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Clevidipine.
NicorandilNicorandil may increase the hypotensive activities of Clevidipine.
NicotineThe metabolism of Clevidipine can be decreased when combined with Nicotine.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Clevidipine.
NilotinibThe metabolism of Clevidipine can be decreased when combined with Nilotinib.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clevidipine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Clevidipine.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clevidipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Clevidipine.
NitroprussideClevidipine may increase the hypotensive activities of Nitroprusside.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Clevidipine.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clevidipine.
OsimertinibThe serum concentration of Clevidipine can be decreased when it is combined with Osimertinib.
PanobinostatThe metabolism of Clevidipine can be decreased when combined with Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.
ParoxetineThe metabolism of Clevidipine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Clevidipine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Clevidipine.
PentobarbitalPentobarbital may increase the hypotensive activities of Clevidipine.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Clevidipine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Clevidipine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Clevidipine.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Clevidipine.
PrazosinPrazosin may increase the hypotensive activities of Clevidipine.
PrazosinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Prazosin.
PrimidonePrimidone may increase the hypotensive activities of Clevidipine.
PromazineThe metabolism of Clevidipine can be decreased when combined with Promazine.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Clevidipine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clevidipine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.
QuinidineThe metabolism of Clevidipine can be decreased when combined with Quinidine.
QuinineThe metabolism of Clevidipine can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Clevidipine.
RanolazineThe metabolism of Clevidipine can be decreased when combined with Ranolazine.
RapacuroniumClevidipine may increase the neuromuscular blocking activities of Rapacuronium.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clevidipine.
RifampicinThe metabolism of Clevidipine can be increased when combined with Rifampicin.
RiociguatThe risk or severity of adverse effects can be increased when Clevidipine is combined with Riociguat.
RisperidoneClevidipine may increase the hypotensive activities of Risperidone.
RitonavirThe metabolism of Clevidipine can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Clevidipine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Clevidipine can be decreased when combined with Ropinirole.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Clevidipine.
SecobarbitalSecobarbital may increase the hypotensive activities of Clevidipine.
SertralineThe metabolism of Clevidipine can be decreased when combined with Sertraline.
SilodosinSilodosin may increase the hypotensive activities of Clevidipine.
SimeprevirThe metabolism of Clevidipine can be decreased when combined with Simeprevir.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Clevidipine.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Clevidipine.
StiripentolThe metabolism of Clevidipine can be decreased when combined with Stiripentol.
TamsulosinTamsulosin may increase the hypotensive activities of Clevidipine.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clevidipine.
TenofovirThe metabolism of Clevidipine can be decreased when combined with Tenofovir.
TerazosinTerazosin may increase the hypotensive activities of Clevidipine.
TerazosinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Terazosin.
TerbinafineThe metabolism of Clevidipine can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Clevidipine can be decreased when it is combined with Teriflunomide.
TheophyllineThe metabolism of Clevidipine can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Clevidipine.
ThiopentalThiopental may increase the hypotensive activities of Clevidipine.
ThioridazineThe metabolism of Clevidipine can be decreased when combined with Thioridazine.
TiclopidineThe metabolism of Clevidipine can be decreased when combined with Ticlopidine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Clevidipine.
TipranavirThe metabolism of Clevidipine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Clevidipine.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clevidipine.
TranylcypromineThe metabolism of Clevidipine can be decreased when combined with Tranylcypromine.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Clevidipine.
TrimazosinTrimazosin may increase the hypotensive activities of Clevidipine.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Clevidipine.
VemurafenibThe serum concentration of Clevidipine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Clevidipine can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Clevidipine.
ZiprasidoneThe metabolism of Clevidipine can be decreased when combined with Ziprasidone.
Food Interactions
  • Grapefruit Juice

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1F
Uniprot ID:
O60840
Molecular Weight:
220675.9 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Ericsson H, Tholander B, Regardh CG: In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37. [PubMed:10072476 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on September 26, 2016 02:13